Dr. Colleen Delaney from Coeptis Therapeutics on the development of next-generation cell therapy technologies for cancer and infectious diseases

In a recent Investor.Coffee interview with host Jack Lifton, Dr. Colleen Delaney, Chief Scientific and Medical Officer at Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), shares insights into the company’s innovative approach to cancer treatment. Dr. Delaney begins with an overview on their commitment to developing universally accessible and cost-effective cellular treatments, including immunotherapy and CAR T-cell therapies for the treatment of cancer and infectious diseases. Dr. Delaney, with her background as a pediatric stem cell transplant physician and pediatric oncologist, emphasizes the company’s use of a platform developed at the Fred Hutch Cancer Center and goes on to explain this to Jack. Regarding the progress towards FDA approval, Coeptis has two Investigational New Drug (IND) applications approved, indicating the advanced stage of their clinical trials. The company’s unique approach includes pool donor manufacturing for scalability and cost-effectiveness. Their primary starting material is umbilical cord blood, considered a clean and prolific source, avoiding the complexities of individual donor testing.